References
- Xiong W, Guo Z, Zeng B, et al. Dacarbazine-Loaded targeted polymeric nanoparticles for enhancing malignant melanoma therapy. Front Bioeng Biotechnol. 2022;10:847901–847911. doi: 10.3389/fbioe.2022.847901.
- Vimla N, Kumar L, Thulkar S, et al. Primary malignant melanoma in ovarian cystic teratoma. Gynecol Oncol. 2002;82(2):380–383. doi: 10.1006/gyno.2001.6223.
- Wilson M, Schucheter L. Chemotherapy for melanoma. Cancer Treat Res. 2016;167:209–229.
- Hafeez A, Kazmi I. Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. Sci Rep. 2017;7(1):16517. doi: 10.1038/s41598-017-16878-1.
- Fagundes T, Madeira T, Melo G, et al. Caffeine improves the cytotoxic effect of dacarbazine on B16F10 murine melanoma cells. Bioorg Chem. 2022;120:105576. doi: 10.1016/j.bioorg.2021.105576.
- Erdmann S, Seidel D, Jahnke H-G, et al. Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. Sci Rep. 2019;9(1):30–41. doi: 10.1038/s41598-018-37188-0.
- Brendel E, Ludwig M, Lathia C, et al. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010;68(1):53–61. doi: 10.1007/s00280-010-1423-9.
- Rajkumar S, Reid J, Novotny R, et al. A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. J Neurooncol. 2000;49(3):255–261. doi: 10.1023/a:1006454427026.
- Bampali E, Germer S, Bauer R, et al. HPLC-UV/HRMS methods for the unambiguous detection of adulterations of ginkgo biloba leaves with sophora japonica fruits on an extract level. Pharm Biol. 2021;59:438–443.
- Paulazo M, Sodero A. Analysis of cholesterol in mouse brain by HPLC with UV detection. PLoS One. 2020;15(1):e0228170. doi: 10.1371/journal.pone.0228170.
- Nahar L, Onder A, Sarker S. A review on the recent advances in HPLC, UHPLC and UPLC analyses of naturally occurring cannabinoids. Phytochem Anal. 2020;31(4):413–457. doi: 10.1002/pca.2906.